SENTRIMED, INC.
Oral lozenges containing Maackia amurensis seed lectin (MASL) that target PDPN to treat oral squamous cell carcinoma
- Sector
- Biotech
- Headquarters
- MULLICA HILL, NJ
- Founded
- 2023
- Latest Form D
- $250K, May 2026
- Total capital
- $1.4M
- Federal grants
- $604K
- 3 awards · 2022–2023
- Rank in peer group#159 of 502
- Private capital raised
- $750K
- 2 Form D · last May 2026
- 5 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 7 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$250K
- Private capital raisedForm D · SEC · 1st filing$500K
- Federal grantHealth and Human S · Phase I · Targeting OSCC cells with a lozenge to treat oral cancer$248K
- Federal grantHealth and Human S · Phase I · Targeting OSCC cells with a lozenge to treat oral cancer$34K
- Federal grantHealth and Human S · Phase I · Targeting OSCC cells with a lozenge to treat oral cancer$323K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
20months
from SENTRIMED, INC.’s first federal award to its first private round.
- First federal award · Jul 2022
- Health and Human S · $323K
- First Form D · Mar 2024
- $500K · 1st Form D
- Awards before first raise
- 3 awards
An association in public records, not a cause or a prediction.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grants#159 · top 32%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Gary Rhodehamel GoldbergResearcherExecutive OfficerLinked by $604K in grants as PI
- Arye RosenExecutive OfficerNamed in SEC Form D filings
- Bradley GalerDirectorNamed in SEC Form D filings
- Christopher LeonardExecutive OfficerNamed in SEC Form D filings
- Jack GoldbergExecutive Officer, DirectorNamed in SEC Form D filings
- Mari Rhodehamel YinExecutive Officer, DirectorNamed in SEC Form D filings
Show all 9 people
- Mari Rhodehamel YinExecutive Officer, DirectorNamed in SEC Form D filings
- Tabbetha Rhodehamel DobbinsDirectorNamed in SEC Form D filings
- William RagatzExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 7- PendingMethods For Detection And Treatment Of CancersUSPTOApplication PCTUS2025059793
- PendingMethods For Detection And Treatment Of CancersUSPTOApplication 63734330
- PendingSoluble Recombinant Human Podoplanin ReceptorUSPTOApplication PCTUS2024046332
Show all 7 patent records
- Methods For Detection And Treatment Of CancersApplication PCTUS2025059793Pending
- Methods For Detection And Treatment Of CancersApplication 63734330Pending
- Soluble Recombinant Human Podoplanin ReceptorApplication PCTUS2024046332Pending
- Maackia Amurensis Seed Lectin IsoformsApplication PCTUS2024046319Pending
- Soluble Recombinant Human Podoplanin ReceptorApplication 63537975Pending
- Maackia Amurensis Seed Lectin IsoformsApplication 63537963Pending
- Maackia Amurensis Seed Lectin IsoformsApplication 19518874Pending
Related companies, and why
- Jupiter Biomedical Research, Inc.Similar federal contract value in Biotech · null in contracts
- Atacama Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Nok Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Oleander Medical Technologies LLCSimilar federal contract value in Biotech · null in contracts
- ACUMEN PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
- StrideBio, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .